β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Cancer, one of the major health problems all over the world, requires more competent drugs for clinical use. One recent possible chemotherapeutic drug under research is β-lapachone. β-lapachone (1,2-naphthoquinone) has promising activity against those tumors showing raised levels of Nicotinamide di-phosphate Quinone Oxidoreductases-1 (NQO1). NQO1 is found to be up-regulated in pancreatic tumor cells, and thus β-lapachone could generate cytotoxicity in various cancers like pancreatic tumors. β-lapachone harborage independent growth and clonogenic cell survival in agar. The cell-killing effects of β-lapachone can be stopped by using dicumarol, an inhibitor of NAD(P)H Quinone Oxidoreductases-1. In previously established pancreatic cancer xenografts in mice, β-lapachone inhibited the tumor growth when given orally rather than when combined with cyclodex-trin to improve its bioavailability.

Original languageEnglish
Pages (from-to)537-540
Number of pages4
JournalCurrent Cancer Drug Targets
Volume22
Issue number7
DOIs
StatePublished - Aug 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • cyclodextrins
  • human pancreatic cancer
  • NAD(P)H quinone oxidoreductase-1
  • quinones
  • reactive oxygen species
  • β-lapachone

Fingerprint

Dive into the research topics of 'β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer'. Together they form a unique fingerprint.

Cite this